Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, discusses the latest PARP inhibitor indications for frontline maintenance in ovarian cancer, as well as the impending results of other PARP inhibitor studies in the ovarian space.
ADVERTISEMENT
ENGAGING EXPERTS
Ovarian Cancer Maintenance: PRIMA, PAOLA-1, VELIA, and Others
06/05/2020
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
June 2024
Volume 10
Issue 3
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Journal of Clinical Pathways Newsletter
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement